Molecular imaging of dementia

Psychogeriatrics

Volumn 12, Issue 2, 2012, Pages 106-114

  Mori, Takaaki ^a,b   Maeda, Jun ^a   Shimada, Hitoshi ^a   Higuchi, Makoto ^a   Shinotoh, Hitoshi ^a   Ueno, Shu ichi ^b   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

A ; Alzheimer's disease (AD); Amyloid; Dementia; Microglia; Positron emission tomography (PET)

Indexed keywords

PITTSBURGH COMPOUND B;

ALZHEIMER DISEASE; CELL ACTIVATION; DEMENTIA; HUMAN; MICROGLIA; MOLECULAR IMAGING; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; REVIEW;

ACETYLCHOLINESTERASE; AGED; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION; LEWY BODY DISEASE; MICE; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDONECARBOXYLIC ACID; TAU PROTEINS;

EID: 84862684117     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/j.1479-8301.2012.00409.x     Document Type: Review

References (65)

1. Wimo A, Winblad B, Aguero-Torres H, von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 2003; 17: 63-67.
2. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42: 1097-1105.
3. DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 2003; 302: 830-834.
4. Drzezga A, Grimmer T, Riemenschneider M etal. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 2005; 46: 1625-1632.
5. Higuchi M, Lee VMY, Trojanowski JQ. Pathobiological features in neurodegenerative diseases: an overview. In: Numura Y, Takeda T, Okuma Y, eds. International Congress Series 1260: The Senescence-Accelerated Mouse (SAM): An Animal Model of Senescence. Amsterdam: Elsevier, 2004; 69-75.
6. Braak H, Braak E. Neuropathological staging of Alzheiner-related changes. Acta Neuropathol 1991; 82: 239-259.
7. Price JL, Morris JC. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Ann Neurol 1999; 45: 358-368.
8. Higuchi M, Ishihara T, Zhang B etal. Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration. Neuron 2002; 35: 433-446.
9. Higuchi M, Lee VM, Trojanowski JQ. Tau and axonopathy in neurodegenerative disorders. Neuromolecular Med 2002; 2: 131-150.
10. Small GW, Kepe V, Ercoli LM etal. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006; 355: 2652-2663.
11. Klunk WE, Engler H, Nordberg A etal. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319.
12. Näslund J, Haroutunian V, Mohs R etal. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000; 283: 1571-1577.
13. Mintun MA, Larossa GN, Sheline YI etal. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-452.
14. Bacskai BJ, Frosch MP, Freeman SH etal. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007; 64: 431-434.
15. Johnson AE, Jeppsson F, Sandell J etal. AZD2184: a radioligand for sensitive detection of beta-amyloid deposits. J Neurochem 2009; 108: 1177-1186.
16. Kudo Y, Okamura N, Furumoto S etal. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 2007; 48: 553-561.
17. Vandenberghe R, Van Laere K, Ivanoiu A etal. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010; 68: 319-329.
18. Rowe CC, Ackerman U, Browne W etal. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008; 7: 129-135.
19. Choi SR, Golding G, Zhuang Z etal. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 2009; 50: 1887-1894.
20. Juréus A, Swahn BM, Sandell J etal. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem 2010; 114: 784-794.
21. Avid Radiopharmaceuticals, Inc. FDA Advisory Committee Meeting. October 23, 2008. 18F-AV-45: PET Amyloid Plaque Imaging Agent Summary of Development Program and Proposed Phase III Plan.
22. Clark CM, Schneider JA, Bedell BJ etal. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305: 275-283.
23. Klunk WE, Lopresti BJ, Ikonomovic MD etal. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005; 25: 10598-10606.
24. Toyama H, Ye D, Ichise M etal. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging 2005; 32: 593-600.
25. Maeda J, Higuchi M, Inaji M etal. Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Res 2007; 1157: 100-111.
26. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 1995; 14: 457-466.
27. Schilling S, Lauber T, Schaupp M etal. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 2006; 45: 12393-12399.
28. Wirths O, Weis J, Kayed R, Saido TC, Bayer TA. Age-dependent axonal degeneration in an Alzheimer mouse model. Neurobiol Aging 2007; 28: 1689-1699.
29. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 2001; 21: 372-381.
30. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995; 21: 195-218.
31. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007; 27: 9115-9129.
32. Yoshiyama Y, Higuchi M, Zhang B etal. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007; 53: 337-351.
33. Diorio D, Welner SA, Butterworth RF, Meaney MJ, Suranyi-Cadotte BE. Peripheral benzodiazepine binding sites in Alzheimer's disease frontal and temporal cortex. Neurobiol Aging 1991; 12: 255-258.
34. Miyoshi M, Ito H, Arakawa R etal. Quantitative analysis of peripheral benzodiazepine receptor in the human brain using PET with (11)C-AC-5216. J Nucl Med 2009; 50: 1095-1101.
35. Cagnin A, Brooks DJ, Kennedy AM etal. In-vivo measurement of activated microglia in dementia. Lancet 2001; 358: 461-467.
36. Maeda J, Suhara T, Zhang MR etal. Novel peripheral benzodiazepine receptor ligand [11C]DAA1106 for PET: an imaging tool for glial cells in the brain. Synapse 2004; 52: 283-291.
37. Zhang MR, Maeda J, Ogawa M etal. Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain. J Med Chem 2004; 47: 2228-2235.
38. Yasuno F, Ota M, Kosaka J etal. Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry 2008; 64: 835-841.
39. Maeda J, Ji B, Irie T etal. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 2007; 27: 10957-10968.
40. Venneti S, Lopresti BJ, Wang G etal. A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation. J Neurochem 2007; 102: 2118-2131.
41. Ji B, Maeda J, Sawada M etal. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J Neurosci 2008; 28: 12255-12267.
42. Gulyás B, Makkai B, Kása P etal. A comparative autoradiography study in post mortem whole hemisphere human brain slices taken from Alzheimer patients and age-matched controls using two radiolabelled DAA1106 analogues with high affinity to the peripheral benzodiazepine receptor (PBR) system. Neurochem Int 2009; 54: 28-36.
43. Zhang MR, Kumata K, Maeda J etal. 11C-AC-5216: a novel PET ligand for peripheral benzodiazepine receptors in the primate brain. J Nucl Med 2007; 48: 853-861.
44. Yanamoto K, Kumata K, Yamasaki T etal. [18F]FEAC and [18F]FEDAC: two novel positron emission tomography ligands for peripheral-type benzodiazepine receptor in the brain. Bioorg Med Chem Lett 2009; 19: 1707-1710.
45. Yanamoto K, Yamasaki T, Kumata K etal. Evaluation of N-benzyl-N-[11C]methyl-2-(7-methyl-8-oxo-2-phenyl-7, 8-dihydro-9H-purin-9-yl)acetamide ([11C]DAC) as a novel translocator protein (18 kDa) radioligand in kainic acid-lesioned rat. Synapse 2009; 63: 961-971.
46. Maeda J, Zhang MR, Okauchi T etal. In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. J Neurosci 2011; 31: 4720-4730.
47. Miyoshi M, Shinotoh H, Wszolek ZK etal. In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: a PET and MRI study. Parkinsonism Relat Disord 2010; 16: 404-408.
48. Higuchi M, Saido TC, Suhara T. Animal models of tauopathies. Neuropathology 2006; 26: 491-497.
49. Higuchi M, Maeda J, Ji B etal. In-vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: insights from neuroimaging research in humans and rodent models. Biochim Biophys Acta 2010; 1802: 373-388.
50. Emre M, Aarsland D, Brown R etal. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-1707.
51. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-414.
52. Asahina M, Shinotoh H, Hirayama K etal. Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET. Acta Neurol Scand 1995; 91: 437-443.
53. Namba H, Iyo M, Fukushi K etal. Human cerebral acetylcholinesterase activity measured with positron emission tomography: procedure, normal values and effect of age. Eur J Nucl Med 1999; 26: 135-143.
54. Iyo M, Namba H, Fukushi K etal. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997; 349: 1805-1809.
55. Kuhl DE, Koeppe RA, Minoshima S etal. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 1999; 52: 691-699.
56. Shinotoh H, Namba H, Yamaguchi M etal. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Ann Neurol 1999; 46: 62-69.
57. Bohnen NI, Kaufer DI, Ivanco LS etal. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60: 1745-1748.
58. Shimada H, Hirano S, Shinotoh H etal. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009; 73: 273-278.
59. Hirano S, Shinotoh H, Shimada H etal. Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia. Brain 2010; 133: 2058-2068.
60. Hirano S, Eckert T, Flanagan T, Eidelberg D. Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease. Mov Disord 2009; 24: 725-731.
61. Ota T, Shinotoh H, Fukushi K etal. Estimation of plasma IC50 of donepezil for cerebral acetylcholinesterase inhibition in patients with Alzheimer disease using positron emission tomography. Clin Neuropharmacol 2010; 33: 74-78.
62. Mormino EC, Kluth JT, Madison CM etal. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009; 132: 1310-1323.
63. Jack CR Jr, Lowe VJ, Weigand SD etal. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132: 1355-1365.
64. Jack CR Jr, Knopman DS, Jagust WJ etal. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-128.
65. Sperling RA, Aisen PS, Beckett LA etal. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-292.